Chiesi Acquires KalVista Therapeutics in $1.9 Billion Deal
Italian pharmaceutical company Chiesi has finalized its acquisition of KalVista Therapeutics for $1.9 billion, expanding its rare-disease portfolio with an approved treatment for a genetic swelling disorder.
The deal values KalVista at $27 per share, representing a 40% premium over its closing stock price on the previous Tuesday. The company’s lead product, Ekterly, is an oral medication designed to treat acute swelling attacks in patients with hereditary angioedema.
Biotech Earnings Roundup: Q1 2024 Financial Reports
Major biotech firms have released their first-quarter earnings. Companies reporting include:
- Biogen
- AstraZeneca
- Regeneron Pharmaceuticals
- AbbVie
- GlaxoSmithKline (GSK)
FDA Accelerates Drug Approvals with Real-Time Trial Reviews
The U.S. Food and Drug Administration (FDA) announced a new initiative to expedite drug approvals by reviewing trial data in real time. This program will initially focus on oncology studies conducted by AstraZeneca and Amgen, aiming to bring therapies to market more swiftly.
Why This Matters for Biotech
Real-time data review is expected to reduce delays in drug development, addressing critical unmet medical needs faster. The FDA’s move aligns with broader efforts to streamline regulatory processes in the biotech sector.
Related articles
Supreme Court Blocks Restrictions on Abortion Pill Mifepristone, Ensuring Continued Access
WASHINGTON — The Supreme Court on Thursday preserved women’s access to a drug used in the most common method of abortion, rejecting lower-court restri...
Dr. Makary's Exit and the Future of Cassidy's Senate Seat: Key Health Policy Shifts
This week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he...
Who Will Lead the FDA Next? The Search for a New Commissioner Heats Up
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to...
Study Links High Air Pollution to Increased Post-Surgical Complications on Utah’s Wasatch Front
New research on Utah’s Wasatch Front—which occasionally experiences the worst air quality in the nation—has found an association between high air poll...
BeOne Secures FDA Approval for Novel Lymphoma Cell Therapy, Advancing Autoimmune Treatment Pipeline
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Biotech’s cell therapy boo...
Why Major Digital Health Companies Are Absent from Medicare’s Chronic Care Pilot Program
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it deli...
Biogen’s Tau-Targeting Alzheimer’s Drug Shows Promise in Phase 2 Trial; Takeda to Cut 4,500 Jobs by 2026
Rise and shine, everyone, another busy day is on the way. And it is getting off to a pleasant start here on the Pharmalot campus, where clear blue ski...
Three Years of Declining Overdose Deaths: Cautious Optimism and Lingering Concerns
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. STAT’s Helen Branswel...